AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02638831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Description: Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
Study NCT01190683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
Study NCT01190683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
Study NCT01190683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol and calcium carbonate
Description: 60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
Study NCT04189939 — intervention group
Intervention type: OTHER
Intervention: clinical assessments
Description: Behavioral tasks will be executed via a computer interface. Below, we provide an estimated timeline for each visit and subsequently provide detail for the relevant stages.~Each participant's visit will last approximately 4-5 hours. Each visit will consist of the following tasks (in this order):
Study NCT01190683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose placebo
Description: similar number of granules and tablets as active group
Study NCT01694290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemical Cold Pack
Study NCT04094987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inter-fascial pressure
Description: The pressure between the fascia and the pressure line added to the catheter tip will be measured.
Study NCT04163133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two days later trigger than regular timing
Description: During ovarian stimulation, two days later of trigger after three follicles reach 17mm bilateral with contineous using of Gonadotrophin in antagonist protocol.
Study NCT01190683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactose granules and tablets
Description: one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
Study NCT01399463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty performed via Paclitaxel Eluting Balloon catheter
Study NCT01190683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose granules and tablets
Description: one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
Study NCT03361436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03361436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03361436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03361436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01531452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 d1,repeated q21d
Study NCT01531452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s1
Description: 80mg/m2/d, d1-14,repeated q21d
Study NCT00916032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
Description: Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
Study NCT00453986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose
Study NCT01399463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty via DES
Description: Angioplasty performed via commonly used Drug Eluting Stents
Study NCT00453986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ACWY
Description: One subcutaneous dose
Study NCT00453986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: One intramuscular dose
Study NCT00303862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00303862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03281473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy 1
Description: PEEP titration according to transpulmonary-end-expiratory pressure
Study NCT03281473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy 2
Description: PEEP titration according to chest wall elastance measurement
Study NCT01806987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KITS Program
Description: The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
Study NCT01459861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canal Block and Capsular Injection
Description: Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
Study NCT01459861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block with Tibial Nerve Block
Description: Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
Study NCT04507386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a STAND for health
Description: The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
Study NCT01824251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Study NCT00794183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT device settings
Description: Comparision of A-V delay settings
Study NCT05260996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilot Group
Description: 12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
Study NCT00583986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI with top mounted actuation indicator
Description: Levalbuterol HFA MDA with top mounted actuation indicator
Study NCT00513461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03477253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: The use of laparoscopic cholecystectomy in management of acute calculous cholecysitits
Study NCT00513461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02390531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl
Study NCT03619460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric extraction
Description: Only Piezoelectric device will be used for surgical wisdom teeth extraction
Study NCT03619460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional extraction
Description: Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
Study NCT00992069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Oral dose of 600 mg daily, taken in the evening
Study NCT03973411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic ondansetron
Description: Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
Study NCT00992069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: Single oral dose of 400 mg in the morning
Study NCT03973411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pacients will receibe standard spinal anesthesia
Study NCT05170152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography-guided injection
Description: ultrasonography-guided injection
Study NCT05170152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pullae A1 release
Description: ultrasonography-guided pullae A1 release
Study NCT02430649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Study NCT02430649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT01644292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPIC WheelS
Description: EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
Study NCT00563641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very early surfactant and bubble NCPAP
Description: For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
Study NCT00563641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bubble NCPAP
Description: Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria.
Study NCT01780038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receipt of Genetic Results
Description: Participants will receive the results of genotyping for RS1051730
Study NCT01254123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide infusion
Description: On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.~Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.
Study NCT01254123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion.
Description: On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.
Study NCT02151266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Cognitive retraining
Description: Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
Study NCT02151266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Only
Study NCT02151266 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching and Flexibility
Study NCT01349920 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
Study NCT01811212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01811212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00812279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distillation based smoking article (SMAR cigarette)
Description: Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
Study NCT00812279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional cigarette
Description: Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
Study NCT00812279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation
Description: Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
Study NCT01458470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: oral tablet, 1 BID, 24 weeks
Study NCT01458470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, 1 BID, 24 weeks
Study NCT04167605 — intervention group
Intervention type: OTHER
Intervention: Bone metastasis
Description: Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.
Study NCT04167605 — intervention group
Intervention type: OTHER
Intervention: Breast cancer metastatic to bone
Description: Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
Study NCT01185067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Description: Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
Study NCT01185067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Description: Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
Study NCT01942681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propiverine Hydrochloride
Description: Administrate Propiverine Hydrochloride for 12 weeks
Study NCT04272502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Description: Each arm has a different order for taking IP
Study NCT01780038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No results given
Description: Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
Study NCT03735264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study NCT02244255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOMAX® capsules
Study NCT02244255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascending doses of HYTRIN® capsules
Study NCT02635802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time >1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min.
Study NCT02635802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
Study NCT02635802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil+Lidocaine
Description: a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time >1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
Study NCT02635802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
Study NCT02741401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual post-operative care
Description: Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
Study NCT02741401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual post-operative care
Description: Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
Study NCT02741401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-foot massage
Description: Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
Study NCT01995487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNIR
Description: drug-eluting stent
Study NCT01995487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute
Description: drug-eluting stent
Study NCT04523155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically tailored meals
Description: 10 meals per week for 3 months
Study NCT04602884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath biopsy sampling using the ReCIVA Breath Sampler
Description: Breath biopsy sampling using the ReCIVA Breath Sampler
Study NCT04602884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath biopsy sampling using the ReCIVA Breath Sampler
Description: Breath biopsy sampling using the ReCIVA Breath Sampler
Study NCT02707692 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluarix
Description: Intramuscular injection with Fluarix® .
Study NCT00843609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigator continuous glucose monitor (Freestyle Navigator®)
Description: Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
Study NCT02707692 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax
Description: Intramuscular injection with Pneumovax.
Study NCT02707692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Intramuscular injection with sterile saline (placebo).
Study NCT00513461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies